The effect of gonadotropin releasing hormone analog leuprolide treatment on body fat distribution in idiopathic central precocious puberty
Küçük Resim Yok
Tarih
2011
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Turkish Journal of Pediatrics
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Gonadotropin-releasing hormone analog (GnRHa) therapy is used in idiopathic central precocious puberty (ICPP) worldwide. It has also been shown that during this therapy, body mass index (BMI) increases slightly as a side effect. We investigated the side effects of GnRHa treatment in ICPP on body composition and insulin resistance (IR). Twenty girls (7.55 +/- 1.02 y) with ICPP were treated with GnRHa (leuprolide) for an average of 20.83 +/- 4.8 months. Bioelectrical Impedance Analysis (BIA) was used to measure the body's fat balance. Nine patients out of 20 (45%) had significant gain weight. We showed a significant elevation in trunk fat mass compare to baseline values (p < 0.01). These nine patients had high homeostasis model assessment (HOMA)-IR and low glucose/insulin (G/I) index. This study showed a slight increase in BMI, moderate increase in total body fat, and exaggerated elevation in trunk fat mass and IR in GnRHa-treated ICPP children.
Açıklama
Turkish Journal of Pediatrics
Anahtar Kelimeler
Kaynak
Turkish Journal of Pediatrics
WoS Q Değeri
Scopus Q Değeri
Cilt
53
Sayı
1
Künye
BİLİR, P., & AKINCI, A. (2011). The effect of gonadotropin releasing hormone analog leuprolide treatment on body fat distribution in idiopathic central precocious puberty. Turkish Journal of Pediatrics, 53(1), 27–29.
